Home » Topics » BioWorld Science

BioWorld Science
RSS

Second phase III trial of phenserine for Alzheimer's disease

June 18, 2004

Sepracor resubmits Estorra NDA

June 18, 2004

FDA approves Rapinex powder for oral suspension 20 mg

June 18, 2004

Disappointing preliminary phase IIa results for NGD-2000-1 in RA

June 18, 2004

Clinical efficacy of a BAY-43-9006 combination regimen in advanced melanoma

June 18, 2004

Vasogen updates Celacade phase III program

June 18, 2004

Enzon strengthens pipeline during Q3 through Onco TCS addition

June 18, 2004

NCX-911 may benefit ED patients with dysfunctional endogenous NO production

June 18, 2004

Treatment options for restless legs syndrome

June 18, 2004

Dopamine D4 receptor agonist ABT-724 may offer safe and effective treatment of erectile dysfunction

June 18, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...